The estimated Net Worth of Morana Jovan Embiricos is at least $906 Tausend dollars as of 24 June 2022. Morana Embiricos owns over 140,374 units of AlloVir stock worth over $192,190 and over the last 10 years Morana sold ALVR stock worth over $713,874.
Morana has made over 7 trades of the AlloVir stock since 2014, according to the Form 4 filled with the SEC. Most recently Morana exercised 140,374 units of ALVR stock worth $603,608 on 24 June 2022.
The largest trade Morana's ever made was buying 2,900,000 units of AlloVir stock on 3 August 2020 worth over $49,300,000. On average, Morana trades about 215,098 units every 173 days since 2014. As of 24 June 2022 Morana still owns at least 252,881 units of AlloVir stock.
You can see the complete history of Morana Embiricos stock trades at the bottom of the page.
Morana's mailing address filed with the SEC is C/O ALLOVIR, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... und Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
AlloVir executives and other stock owners filed with the SEC include: